PURPOSE: To determine the neuropathologic correlates of antemortem hydrogen 1 ((1)H) magnetic resonance (MR) spectroscopy metabolite measurements in subjects with Alzheimer disease (AD)-type pathology. MATERIALS AND METHODS: This study was approved by the institutional review board and was compliant with HIPAA regulations. Informed consent was obtained from each subject. The authors identified 54 subjects who underwent antemortem (1)H MR spectroscopy and were clinically healthy or had AD-type pathology with low to high likelihood of AD according to National Institute on Aging-Reagan neuropathologic criteria at autopsy. They investigated the associations between (1)H MR spectroscopy metabolite measurements and Braak neurofibrillary tangle stage (Braak stage), neuritic plaque score, and AD likelihood, with adjustments for subject age, subject sex, and time between (1)H MR spectroscopy and death. RESULTS: Decreases in N-acetylaspartate-to-creatine ratio, an index of neuronal integrity, and increases in myo-inositol-to-creatine ratio were associated with higher Braak stage, higher neuritic plaque score, and greater likelihood of AD. The N-acetylaspartate-to-myo-inositol ratio proved to be the strongest predictor of the pathologic likelihood of AD. The strongest association observed was that between N-acetylaspartate-to-myo-inositol ratio and Braak stage (R(N)(2) = 0.47, P < .001). CONCLUSION: Antemortem (1)H MR spectroscopy metabolite changes correlated with AD-type pathology seen at autopsy. The study findings validated (1)H MR spectroscopy metabolite measurements against the neuropathologic criteria for AD, and when combined with prior longitudinal (1)H MR spectroscopy findings, indicate that these measurements could be used as biomarkers for disease progression in clinical trials. (c) RSNA, 2008.
PURPOSE: To determine the neuropathologic correlates of antemortem hydrogen 1 ((1)H) magnetic resonance (MR) spectroscopy metabolite measurements in subjects with Alzheimer disease (AD)-type pathology. MATERIALS AND METHODS: This study was approved by the institutional review board and was compliant with HIPAA regulations. Informed consent was obtained from each subject. The authors identified 54 subjects who underwent antemortem (1)H MR spectroscopy and were clinically healthy or had AD-type pathology with low to high likelihood of AD according to National Institute on Aging-Reagan neuropathologic criteria at autopsy. They investigated the associations between (1)H MR spectroscopy metabolite measurements and Braak neurofibrillary tangle stage (Braak stage), neuritic plaque score, and AD likelihood, with adjustments for subject age, subject sex, and time between (1)H MR spectroscopy and death. RESULTS: Decreases in N-acetylaspartate-to-creatine ratio, an index of neuronal integrity, and increases in myo-inositol-to-creatine ratio were associated with higher Braak stage, higher neuritic plaque score, and greater likelihood of AD. The N-acetylaspartate-to-myo-inositol ratio proved to be the strongest predictor of the pathologic likelihood of AD. The strongest association observed was that between N-acetylaspartate-to-myo-inositol ratio and Braak stage (R(N)(2) = 0.47, P < .001). CONCLUSION: Antemortem (1)H MR spectroscopy metabolite changes correlated with AD-type pathology seen at autopsy. The study findings validated (1)H MR spectroscopy metabolite measurements against the neuropathologic criteria for AD, and when combined with prior longitudinal (1)H MR spectroscopy findings, indicate that these measurements could be used as biomarkers for disease progression in clinical trials. (c) RSNA, 2008.
Authors: W Huang; G E Alexander; L Chang; H U Shetty; J S Krasuski; S I Rapoport; M B Schapiro Journal: Neurology Date: 2001-08-28 Impact factor: 9.910
Authors: K Kantarci; C R Jack; Y C Xu; N G Campeau; P C O'Brien; G E Smith; R J Ivnik; B F Boeve; E Kokmen; E G Tangalos; R C Petersen Journal: Neurology Date: 2000-07-25 Impact factor: 9.910
Authors: W Huang; G E Alexander; E M Daly; H U Shetty; J S Krasuski; S I Rapoport; M B Schapiro Journal: Am J Psychiatry Date: 1999-12 Impact factor: 18.112
Authors: W M Brooks; C A Stidley; H Petropoulos; R E Jung; D C Weers; S D Friedman; M A Barlow; W L Sibbitt; R A Yeo Journal: J Neurotrauma Date: 2000-08 Impact factor: 5.269
Authors: M Catani; A Cherubini; R Howard; R Tarducci; G P Pelliccioli; M Piccirilli; G Gobbi; U Senin; P Mecocci Journal: Neuroreport Date: 2001-08-08 Impact factor: 1.837
Authors: F Jessen; W Block; F Träber; E Keller; S Flacke; A Papassotiropoulos; R Lamerichs; R Heun; H H Schild Journal: Neurology Date: 2000-09-12 Impact factor: 9.910
Authors: Gülin Oz; Manda L Vollmers; Christopher D Nelson; Ryan Shanley; Lynn E Eberly; Harry T Orr; H Brent Clark Journal: Exp Neurol Date: 2011-09-22 Impact factor: 5.330
Authors: Radhika Srinivasan; Joanna J Phillips; Scott R Vandenberg; Mei-Yin C Polley; Gabriela Bourne; Alvin Au; Andrea Pirzkall; Soonmee Cha; Susan M Chang; Sarah J Nelson Journal: Neuro Oncol Date: 2010-07-20 Impact factor: 12.300
Authors: Eric M McDade; Bradley F Boeve; Julie A Fields; Neeraj Kumar; Rosa Rademakers; Matt C Baker; Bsc David S Knopman; Ronald C Petersen; Clifford R Jack; Kejal Kantarci Journal: J Neuroimaging Date: 2012-05-21 Impact factor: 2.486
Authors: Jean-Pierre Dollé; Jeffrey M Rodgers; Kevin D Browne; Thomas Troxler; Feng Gai; Douglas H Smith Journal: Neurobiol Dis Date: 2018-05-31 Impact factor: 5.996
Authors: Giovanni B Frisoni; Nick C Fox; Clifford R Jack; Philip Scheltens; Paul M Thompson Journal: Nat Rev Neurol Date: 2010-02 Impact factor: 42.937